Dollar rebounds despite Fed independence worries; euro slips
Trevi Therapeutics, Inc. (NASDAQ:TRVI) stock has reached a remarkable 52-week high, touching $7.43 amidst a period of significant volatility in the biopharmaceutical sector. With a market capitalization of $662 million, the company maintains a strong liquidity position, evidenced by a current ratio of 15.38. According to InvestingPro data, analyst price targets range from $11 to $29, suggesting potential upside. This peak represents a substantial gain for the company, which has seen an impressive 1-year return of 153.31% and a remarkable six-month gain of 127.62%. Investors have shown increased confidence in Trevi’s strategic direction and pipeline of treatments, propelling the stock to new heights. The company’s performance is particularly notable in a year marked by challenging market conditions, highlighting the strong investor belief in Trevi’s potential for growth and innovation in its therapeutic areas. InvestingPro subscribers can access 10 additional key insights about TRVI, including detailed financial health scores and comprehensive valuation metrics in the Pro Research Report.
In other recent news, Trevi Therapeutics has reported positive results from its Phase 2b CORAL trial, which evaluated the investigational therapy Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The trial successfully met its primary endpoint, showing significant reductions in cough frequency across all doses tested. This marks a crucial development as there are currently no approved therapies for chronic cough in IPF patients. Additionally, analysts at H.C. Wainwright have initiated coverage on Trevi Therapeutics with a Buy rating and a $21 price target, citing the potential of Haduvio in treating refractory chronic cough (RCC) and IPF-CC. B.Riley analysts also maintained a Buy rating and a $20 target, highlighting the promising data from the Phase 2a RIVER trial. Stifel analysts have reiterated a Buy rating with a $15 target, emphasizing the unique mechanism of action of Haduvio and the high-quality study design. Trevi plans to engage with the FDA in an End-of-Phase 2 meeting later this year, aiming to initiate a Phase 3 program in the first half of 2026. These recent developments underscore the growing confidence in Haduvio’s potential to address unmet medical needs in chronic cough conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.